Efficacy and Safety of Transitioning to Lemborexant from Z-drug, Suvorexant, and Ramelteon in Japanese Insomnia Patients: An Open-label, Multicenter Study
ConclusionsDirect transition to LEM may be a valid treatment option for patients with insomnia who are dissatisfied with current treatment.Trial RegistrationClinicalTrials.gov identifier, NCT04742699.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Ambien | Drugs & Pharmacology | Eszopiclone | Insomnia | Japan Health | Lunesta | Melatonin | Study